Clinical effectiveness of enzyme replacement therapy with galsulfase in mucopolysaccharidosis type VI treatment: Systematic review-Reference-Cited by-同舟云学术

Clinical effectiveness of enzyme replacement therapy with galsulfase in mucopolysaccharidosis type VI treatment: Systematic review

Published:2019-01 Issue:1 Volume:42 Page:66-76
ISSN:0141-8955
Container-title:Journal of Inherited Metabolic Disease
language:en
Short-container-title:Jrnl of Inher Metab Disea

Author:

Gomes Dalila Fernandes¹²,Gallo Luciana Guerra³,Leite Betânia Ferreira⁴,Silva Roberta Borges¹,da Silva Everton Nunes⁵

Affiliation:

1. Faculty of Health SciencesUniversity of Brasilia Brasilia Brazil

2. Post‐Graduation Program in Collective Health, Health Sciences SchoolDarcy Ribeiro University Campus, University of Brasilia Asa Norte, Brasília 70910‐900 Brazil

3. Faculty of MedicineUniversity of Brasilia Brasilia Brazil

4. Paulista School of MedicineFederal University of São Paulo São Paulo Brazil

5. Faculty of CeilândiaUniversity of Brasília Brasília Brazil

Publisher

Wiley

Subject

Genetics(clinical),Genetics

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jimd.12028

Reference33 articles.

1. Mucopolysaccharidosis type VI: A predominantly cardiac phenotype associated with homozygosity for p.R152W mutation in theARSBgene

2. Prevalence of Lysosomal Storage Disorders

3. Incidence of the mucopolysaccharidoses in Western Australia

4. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI;Brunelli MJ;Cochrane Database Syst Rev,2016

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database;Frontiers in Pharmacology;2024-08-05

2. Metabolic diseases;Translational Glycobiology in Human Health and Disease;2024

3. Increased Cerebral Serum Amyloid A2 and Parameters of Oxidation in Arylsulfatase B (N-Acetylgalactosamine-4-Sulfatase)-Null Mice;Journal of Alzheimer's Disease Reports;2023-06-02

4. Advances in therapies for neurological lysosomal storage disorders;Journal of Inherited Metabolic Disease;2023-05-02

5. Increased Cerebral Serum Amyloid A2 and Parameters of Oxidation in Arylsulfatase B (N-Acetylgalactosamine-4-Sulfatase)-Null Mice;2023-04-03